Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst is developing Firdapse (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse has the potential to treat other neuromuscular disorders that are resistant to currently approved therapies. For more information, visit the company’s website at www.catalystpharma.com.